Atossa Therapeutics, Inc. Common Stock
Symbol: ATOS (NASDAQ)
0.98
▲ (1.67%) 0.016
Company Description:
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Key Stats
- Today's Open: $0.984
- Today's High: $0.984
- Today's Low: $0.981
- Today's Volume: 277
- Yesterday Close: $0.9649
- Yesterday High: $1.015
- Yesterday Low: $0.9616
- Yesterday Volume: 649.03K
- Last Min Volume: 76
- Last Min High: $0.981
- Last Min Low: $0.981
- Last Min VWAP: $0.981
Company Profile
- Name: Atossa Therapeutics, Inc. Common Stock
- Website: https://www.atossatherapeutics.com
- Listed Date: 2012-11-08
- Location: SEATTLE, WA
- Market Status: Active
- CIK Number: 0001488039
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $130.46M
- Round Lot: 100
- Outstanding Shares: 129.17M
- Asset Type: CS
RECENT FILINGS FOR ATOS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-21 | 4 | View |
| 2025-10-21 | 3 | View |
| 2025-10-14 | 8-K | View |
| 2025-09-26 | 8-K | View |
| 2025-09-08 | 8-K | View |
| 2025-08-21 | 8-K | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-07-29 | SCHEDULE 13G/A | View |
| 2025-07-16 | SCHEDULE 13G/A | View |
| 2025-05-22 | 4 | View |
| 2025-05-16 | 4 | View |
| 2025-05-16 | 4 | View |
| 2025-05-16 | 4 | View |
| 2025-05-16 | 4 | View |
| 2025-05-16 | 4 | View |
| 2025-05-16 | 4 | View |
| 2025-05-16 | 4 | View |
| 2025-05-16 | 4 | View |
| 2025-05-13 | 10-Q | View |
Latest News on ATOS